Understanding the Current Rating
The 'Hold' rating assigned to Makers Laboratories Ltd indicates a balanced stance for investors. It suggests that while the stock is not currently a strong buy, it also does not warrant a sell recommendation. This rating reflects a combination of factors including the company’s quality, valuation, financial trend, and technical outlook. Investors should interpret this as a signal to maintain existing positions while monitoring developments closely.
Quality Assessment
As of 17 September 2026, Makers Laboratories Ltd exhibits a below-average quality grade. The company’s long-term fundamental strength remains modest, with an average Return on Capital Employed (ROCE) of 8.06%. This figure indicates moderate efficiency in generating profits from capital investments. Over the past five years, net sales have grown at an annual rate of 6.39%, while operating profit has increased by 13.27%. Although these growth rates are positive, they reflect a relatively cautious expansion pace within the pharmaceuticals and biotechnology sector.
Valuation Perspective
The stock currently holds a fair valuation grade. With a Return on Equity (ROE) of 3.2 and a Price to Book Value ratio of 1.5, Makers Laboratories Ltd is trading at a discount compared to its peers’ historical averages. This valuation suggests that the market is pricing the stock conservatively, potentially reflecting concerns about growth sustainability or sector-specific risks. Despite this, the stock’s valuation remains reasonable, offering a balanced risk-reward profile for investors.
Financial Trend and Recent Performance
The financial trend for Makers Laboratories Ltd is very positive as of 17 September 2026. The company has demonstrated strong recent growth, with net profit increasing by 29.21% in the latest quarter. This follows three consecutive quarters of positive results, signalling improving operational performance. Quarterly net sales reached ₹42.77 crores, growing at 21.7% compared to the previous four-quarter average, while quarterly PBDIT hit a high of ₹6.96 crores. Additionally, the debtors turnover ratio stands at a robust 7.08 times, indicating efficient receivables management.
Despite these encouraging short-term results, it is important to note that over the past year, profits have declined by 61.3%. This contrast between recent quarterly improvements and annual profit contraction highlights the volatility and challenges the company faces. Investors should weigh these factors carefully when considering the stock’s outlook.
Technical Outlook
Technically, Makers Laboratories Ltd is rated bullish. The stock has delivered strong market-beating returns across multiple timeframes as of 17 September 2026. It has gained 2.53% in the last trading day, 3.27% over the past week, and an impressive 17.82% in the last month. Over three months, the stock has risen by 24.08%, and over six months by 19.26%. Year-to-date returns stand at 56.16%, while the one-year return is 30.25%. This performance outpaces the BSE500 index over the last three years, one year, and three months, reflecting sustained investor interest and positive momentum.
Shareholding and Market Capitalisation
Makers Laboratories Ltd is classified as a microcap company within the Pharmaceuticals & Biotechnology sector. The majority of shares are held by promoters, which often suggests a stable ownership structure and potential alignment of interests with minority shareholders. However, microcap status can also imply higher volatility and liquidity risks, factors that investors should consider alongside the company’s fundamentals.
Summary for Investors
The 'Hold' rating for Makers Laboratories Ltd reflects a nuanced view of the company’s current standing. While the quality grade is below average and long-term growth remains modest, recent financial trends and technical indicators are encouraging. The fair valuation offers a reasonable entry point, but investors should remain cautious given the profit volatility and microcap classification. This rating advises maintaining existing positions rather than initiating new ones or exiting holdings outright.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
What the Mojo Score Indicates
Makers Laboratories Ltd currently holds a Mojo Score of 60.0, which corresponds to the 'Hold' grade. This score is a composite measure derived from multiple parameters including quality, valuation, financial trend, and technical analysis. The score improved by 13 points from 47 to 60 on 04 August 2026, reflecting a more balanced outlook. For investors, this score suggests that the stock is fairly valued with potential for moderate gains, but also carries risks that warrant caution.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Makers Laboratories Ltd faces a competitive and rapidly evolving market environment. The sector is characterised by innovation, regulatory challenges, and fluctuating demand. The company’s moderate growth rates and recent positive financial trends indicate it is navigating these challenges with some success. However, investors should monitor sector developments and company-specific news closely to assess ongoing risks and opportunities.
Investor Takeaway
For investors considering Makers Laboratories Ltd, the current 'Hold' rating advises a measured approach. The stock’s recent performance and technical strength are encouraging, but the below-average quality and profit volatility suggest that caution is warranted. Maintaining existing holdings while observing future quarterly results and market conditions is a prudent strategy. New investors may prefer to wait for clearer signs of sustained growth before committing capital.
Conclusion
In summary, Makers Laboratories Ltd’s 'Hold' rating by MarketsMOJO, last updated on 04 August 2026, reflects a balanced view of the company’s prospects as of 17 September 2026. The stock offers a fair valuation and positive recent financial trends, offset by modest long-term growth and quality concerns. Investors should consider these factors carefully in the context of their portfolio objectives and risk tolerance.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
